
    
      -  INTERACT study: to evaluate the pathological response rate evaluated according to TRG
           scale comparing accelerated radiotherapy on the gross tumour combined plus standard
           radiotherapy to the pelvis in association with chronomodulated capecitabine (XELACRT
           arm) versus oxaliplatin added to standard pelvis radiotherapy and same chronomodulated
           Capecitabine (XELOXRT arm)

        -  LEADER study: to evaluate the impact on local control of local excision in patients who
           had a major clinical response evaluated by MRI and confirmed by TRG 1-2 score.
    
  